SCHEMBL3684337

SCHEMBL3684337

O=C(NCc1ccc(F)cc1)NCc1cn2cc(-c3ccoc3)cc(C(F)(F)F)c2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PTGER2 P43116 1/20 0.38
HDAC1 Q13547 1/20 0.36
METTL3 Q86U44 1/20 0.36
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
ERN1 O75460 1/20 0.35
KLK1 P06870 1/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
CNR2 P34972 1/20 0.34
ENPP2 Q13822 1/20 0.34
TP53 P04637 2/20 0.34
ACHE P22303 1/20 0.34
GAA P10253 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3708239 0.92 GLS (0.40) HDAC6ALDH1A1MEN1KMT2AMETTL3
SCHEMBL3692752 0.90 GLS (0.42) METTL3ROCK2ROCK1RAB9AACHE
SCHEMBL3703006 0.90 TP53 (0.40) ALDH1A1MAPTMEN1KMT2ARAB9A
SCHEMBL3692029 0.85 HIF1A (0.40) KMT2AMETTL3ROCK2ROCK1TP53
SCHEMBL3696031 0.84 MTOR (0.46) ALDH1A1MEN1KMT2AROCK2ROCK1
SCHEMBL3690420 0.83 RAB9A (0.39) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL3790970 0.83 ALDH1A1 (0.46) ALDH1A1KMT2ANPC1RAB9ATP53
SCHEMBL3786911 0.82 TRPV1 (0.42) KMT2AMETTL3ROCK1NPC1RAB9A
SCHEMBL3696257 0.81 ALDH1A1 (0.40) ALDH1A1MAPTKMT2ANPC1RAB9A
SCHEMBL3790494 0.81 KDM4E (0.47) HDAC6ALDH1A1MAPTMETTL3TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
EP-2187883-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2010-05-26 EP disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
WO-2009023179-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections OAT, HAVCR2, CPS1 HDAC6 746/4885ALDH1A1 1337/4885MAPT 1692/4885
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections OAT, HAVCR2, CPS1 HDAC6 746/4885ALDH1A1 1337/4885MAPT 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.